Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial
- DOI
- 10.48620/85449
- Published
- 2024
- Container
- Not recorded
- Publisher
- University of Bern
- Open access
- yes
Credibility signals
limited evidence Score 47/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- supportingPublication license: A publication license was supplied: http://purl.org/coar/access_right/c_abf2. Presence improves reuse transparency, not research validity.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.48620/85449,
title = {Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial},
author = {Kiritsi, Dimitra and Schauer, Franziska and Gewert, Stella and Reineker, Katja and Reimer-Taschenbrecker, Antonia and Schwieger-Briel, Agnes and Ott, Hagen and Schmoor, Claudia and Grishina, Olga and Murrell, Dedee and Stiller, Brigitte and Zahn, Tobias and Nyström, Alexander and Bruckner-Tuderman, Leena},
year = {2024},
doi = {10.48620/85449},
url = {https://doi.org/10.48620/85449}
}RIS
TY - JOUR TI - Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial AU - Kiritsi, Dimitra AU - Schauer, Franziska AU - Gewert, Stella AU - Reineker, Katja AU - Reimer-Taschenbrecker, Antonia AU - Schwieger-Briel, Agnes AU - Ott, Hagen AU - Schmoor, Claudia AU - Grishina, Olga AU - Murrell, Dedee AU - Stiller, Brigitte AU - Zahn, Tobias AU - Nyström, Alexander AU - Bruckner-Tuderman, Leena PY - 2024 DO - 10.48620/85449 UR - https://doi.org/10.48620/85449 ER -
APA
Dimitra, K., Franziska, S., Stella, G., Katja, R., Antonia, R., Agnes, S., Hagen, O., Claudia, S., Olga, G., Dedee, M., Brigitte, S., Tobias, Z., Alexander, N., & Leena, B. (2024). Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial. https://doi.org/10.48620/85449
Source records
- datacite · retrieved 2026-09-26T15:05:53.325Z